KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, SwitzerlandRead More
An "off-the-shelf" therapy that can be used immediately, rather than one that needs to be manufactured individually for each patient (such as chimeric antigen receptor T (CAR-T) cell therapies) and can be a life-saving proposition for patients facing difficult-to-treat diseases, such as many cancers. The promise of bispecific antibodies (bsAbs) comes from their “off-the-shelf” nature and their ability to recognize multiple targets simultaneously. While many of the bsAbs in development fundamentally maintain the heavy and light chain structure of standard antibodies, advances in protein engineering have allowed for development of smaller versions such as BiTEs and DARTs and for more complex versions with extra binding domains appended to the heavy and/or light chains of the antibodies.
For a manufacturing platform to be truly effective at making bsAbs, it should have three key features:
The Selexis’ SUREtechnology Platform™ provides a modular approach to cell line development that not only provides top cell line productivity levels in the industry, but also has sophisticated capabilities to address the myriad of challenges associated with producing complex difficult-to-express proteins, which bsAbs can be. To address the three key capabilities required for bsAbs production, the SUREtechnology Platform™ has: